Open Label, Dose Finding Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Atezolizumab (Primary) ; RG 6146 (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Roche
- 19 Mar 2018 Planned End Date changed from 6 Oct 2020 to 14 Jan 2023.
- 19 Mar 2018 Planned primary completion date changed from 6 Oct 2020 to 14 Jan 2023.
- 22 Jan 2018 Planned End Date changed from 23 Sep 2020 to 6 Oct 2020.